Haleon plc (NYSE:HLN) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lessened its stake in shares of Haleon plc (NYSE:HLN) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 207,468 shares of the company’s stock after selling 3,858 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Haleon were worth $1,979,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Haleon in the 4th quarter worth $39,628,000. Mesirow Financial Investment Management Inc. increased its position in shares of Haleon by 104.3% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 28,112 shares of the company’s stock worth $268,000 after acquiring an additional 14,349 shares during the last quarter. West Family Investments Inc. increased its position in shares of Haleon by 16.8% during the fourth quarter. West Family Investments Inc. now owns 15,746 shares of the company’s stock worth $150,000 after acquiring an additional 2,265 shares during the last quarter. Callan Family Office LLC acquired a new stake in Haleon during the fourth quarter valued at approximately $1,970,000. Finally, Vestmark Advisory Solutions Inc. raised its stake in Haleon by 53.2% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 62,420 shares of the company’s stock valued at $595,000 after buying an additional 21,673 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Down 0.3 %

Shares of NYSE HLN opened at $10.16 on Friday. The firm’s 50-day simple moving average is $9.74 and its 200 day simple moving average is $9.87. The company has a market cap of $45.97 billion, a price-to-earnings ratio of 29.87, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. On average, research analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. Haleon’s dividend payout ratio is presently 58.97%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.